
Aligos Therapeutics Inc
NASDAQ:ALGS

Intrinsic Value
The intrinsic value of one
ALGS
stock under the Base Case scenario is
4.08
USD.
Compared to the current market price of 7.55 USD,
Aligos Therapeutics Inc
is
Overvalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Aligos Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Aligos Therapeutics Inc
Balance Sheet Decomposition
Aligos Therapeutics Inc
Current Assets | 143.2m |
Cash & Short-Term Investments | 137.9m |
Other Current Assets | 5.3m |
Non-Current Assets | 7.5m |
PP&E | 6.9m |
Other Non-Current Assets | 632k |
Free Cash Flow Analysis
Aligos Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Aligos Therapeutics Inc
Revenue
|
3.3m
USD
|
Operating Expenses
|
-89.6m
USD
|
Operating Income
|
-86.4m
USD
|
Other Expenses
|
33.1m
USD
|
Net Income
|
-53.3m
USD
|
ALGS Profitability Score
Profitability Due Diligence
Aligos Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

Score
Aligos Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
ALGS Solvency Score
Solvency Due Diligence
Aligos Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Score
Aligos Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALGS Price Targets Summary
Aligos Therapeutics Inc
Dividends
Current shareholder yield for ALGS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ALGS
stock under the Base Case scenario is
4.08
USD.
Compared to the current market price of 7.55 USD,
Aligos Therapeutics Inc
is
Overvalued by 46%.